Improvement of sexuality after hepatitis C cure with direct acting antivirals.
Zoe MariñoSergio Rodríguez-TajesConcepció BartrésLoreto NácarSabela LensRicard NavinésMyriam CaveroMaría Carlota LondoñoLydia SastreAnna PocurullAngella DafienoRocío Martín-SantosXavier FornsPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
Despite rarely assessed, sexuality is a relevant domain in Quality of Life. We prospectively evaluated the impact of direct-acting antiviral therapy on sexuality in a cohort of 186 patients with chronic hepatitis C (HCV). Sexual dysfunction was assessed by validated scales CSFQ-14/CSFQ-VAS at baseline and one year after treatment finalization. Median age was 55 years and 87% had mild liver disease. Basal prevalence of sexual dysfunction (62%) and fear of HCV transmission (25%) were high. After HCV cure, both sexual dysfunction prevalence and CSFQ-VAS improved (P = .058 and P < .01, respectively), and fear of HCV transmission dropped to 16% (P = .02). These changes were especially relevant in young men (<55), where sexual dysfunction decreased from 48.6% to 29.7% (P = .04) and among non-depressed patients in whom sexual dysfunction decreased from 54.6% to 47% (P < .01). Age and major depression remained as independent factors of sexual dysfunction persistence after HCV cure. Our data suggest that HCV eradication is associated with an improvement in sexuality, in those patients without depression.
Keyphrases
- hepatitis c virus
- end stage renal disease
- oxidative stress
- mental health
- human immunodeficiency virus
- chronic kidney disease
- newly diagnosed
- ejection fraction
- risk factors
- prognostic factors
- peritoneal dialysis
- stem cells
- depressive symptoms
- patient reported outcomes
- middle aged
- bone marrow
- machine learning
- artificial intelligence
- helicobacter pylori infection
- hiv infected
- sleep quality
- antiretroviral therapy
- patient reported